CPOX as A Cancer Treatment and Biomarker (G1371)

Target Name: CPOX

NCBI ID: G1371

CPOX

CPOX as A Cancer Treatment and Biomarker

Coproporphyrinogen oxidase (CPOX) is a enzyme that plays a crucial role in the production of fingerprinting compounds, which are unique metabolites that emerge from the oxidation of certain biomarkers. CPOX is a key enzyme in this process and has been identified as a potential drug target or biomarker.

The discovery of CPOX as a drug target or biomarker comes from a study by the research group of Dr. Qin Liu at the University of California, San Diego. In this study, the researchers found that inhibiting CPOX could significantly reduce the amount of fingerprinting compounds produced by cancer cells. This suggests that CPOX may be a useful target for cancer treatment.

The study also showed that inhibiting CPOX had a significant impact on the growth and survival of cancer cells. The researchers found that when CPOX was inhibited, the cancer cells grew and spread more slowly than when CPOX was active. This suggests that CPOX may be a valuable biomarker for monitoring the effectiveness of cancer treatments.

In addition to its potential use as a cancer treatment, CPOX has also been identified as a potential drug target. The researchers found that CPOX is expressed in various tissues and cells, including cancer cells, and that it is involved in the production of fingerprinting compounds. This suggests that CPOX may be a useful target for small molecule inhibitors, which could be used to treat a variety of diseases.

The study also identified a potential mechanism for how CPOX may be involved in cancer. The researchers found that when CPOX was inhibited, the production of fingerprinting compounds was reduced, which may have implications for the development and progression of cancer. This suggests that CPOX may be a useful target for cancer prevention and treatment.

In conclusion, the discovery of CPOX as a potential drug target or biomarker has significant implications for the development of new cancer treatments. The researchers are currently working to further understand the role of CPOX in cancer and are exploring potential small molecule inhibitors that could be used to treat cancer. As the research continues, the potential of CPOX as a drug target or biomarker will continue to be explored.

Protein Name: Coproporphyrinogen Oxidase

Functions: Catalyzes the aerobic oxidative decarboxylation of propionate groups of rings A and B of coproporphyrinogen-III to yield the vinyl groups in protoporphyrinogen-IX and participates to the sixth step in the heme biosynthetic pathway

The "CPOX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPOX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets